JP2024102055A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024102055A5 JP2024102055A5 JP2024059910A JP2024059910A JP2024102055A5 JP 2024102055 A5 JP2024102055 A5 JP 2024102055A5 JP 2024059910 A JP2024059910 A JP 2024059910A JP 2024059910 A JP2024059910 A JP 2024059910A JP 2024102055 A5 JP2024102055 A5 JP 2024102055A5
- Authority
- JP
- Japan
- Prior art keywords
- neutralizing agent
- individual
- combination according
- tumor
- nkg2a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 21
- 230000003472 neutralizing effect Effects 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 12
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 12
- 101150069255 KLRC1 gene Proteins 0.000 claims 10
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims 10
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 10
- 230000033607 mismatch repair Effects 0.000 claims 9
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108020004414 DNA Proteins 0.000 claims 4
- 108091092878 Microsatellite Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 229950009791 durvalumab Drugs 0.000 claims 3
- 229950001907 monalizumab Drugs 0.000 claims 3
- 102100028843 DNA mismatch repair protein Mlh1 Human genes 0.000 claims 2
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 claims 2
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 claims 2
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 claims 2
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 claims 2
- 229910015837 MSH2 Inorganic materials 0.000 claims 2
- 208000032818 Microsatellite Instability Diseases 0.000 claims 2
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 claims 2
- 102100037480 Mismatch repair endonuclease PMS2 Human genes 0.000 claims 2
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000004075 alteration Effects 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 206010055114 Colon cancer metastatic Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims 1
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010038111 Recurrent cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000005975 antitumor immune response Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 102000057310 human KLRC1 Human genes 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671521P | 2018-05-15 | 2018-05-15 | |
| US62/671,521 | 2018-05-15 | ||
| PCT/EP2019/062305 WO2019219658A1 (en) | 2018-05-15 | 2019-05-14 | Treatment of cancer |
| JP2020563542A JP7531404B2 (ja) | 2018-05-15 | 2019-05-14 | 癌の処置 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020563542A Division JP7531404B2 (ja) | 2018-05-15 | 2019-05-14 | 癌の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024102055A JP2024102055A (ja) | 2024-07-30 |
| JP2024102055A5 true JP2024102055A5 (enExample) | 2024-11-01 |
Family
ID=66752041
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020563542A Active JP7531404B2 (ja) | 2018-05-15 | 2019-05-14 | 癌の処置 |
| JP2024059910A Pending JP2024102055A (ja) | 2018-05-15 | 2024-04-03 | 癌の処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020563542A Active JP7531404B2 (ja) | 2018-05-15 | 2019-05-14 | 癌の処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12209126B2 (enExample) |
| EP (1) | EP3793607A1 (enExample) |
| JP (2) | JP7531404B2 (enExample) |
| KR (1) | KR102885515B1 (enExample) |
| CN (1) | CN112203691A (enExample) |
| AU (2) | AU2019270277B9 (enExample) |
| CA (1) | CA3099820A1 (enExample) |
| EA (1) | EA202092696A1 (enExample) |
| IL (1) | IL278618B2 (enExample) |
| MA (1) | MA52627A (enExample) |
| SG (1) | SG11202011117VA (enExample) |
| TW (1) | TW202011989A (enExample) |
| WO (1) | WO2019219658A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202007781TA (en) | 2014-09-16 | 2020-09-29 | Innate Pharma | Treatment Regimens Using Anti-NKG2A Antibodies |
| EA202092147A1 (ru) | 2018-03-13 | 2021-03-04 | Иннейт Фарма | Лечение рака головы и шеи |
| WO2021219048A1 (zh) * | 2020-04-30 | 2021-11-04 | 迈威(上海)生物科技股份有限公司 | 一种靶向nkg2a和pd-l1的双特异性抗体及应用 |
| CN116096754A (zh) * | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| US20230183296A1 (en) * | 2020-05-13 | 2023-06-15 | Nanjing Legend Biotech Co., Ltd. | Compositions and methods for reducing host rejection of allogeneic cells using simian icp47 and variants thereof |
| WO2023284874A1 (zh) * | 2021-07-16 | 2023-01-19 | 克莱格医学有限公司 | 用于肿瘤免疫学的组合物和方法 |
| MX2024004145A (es) * | 2021-10-04 | 2024-04-22 | Servier Lab | Terapia del cancer dirigida a nkg2a. |
| JP2025500845A (ja) * | 2021-12-14 | 2025-01-15 | ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Ｃｄ９４／ｎｋｇ２ａヘテロ二量体ポリペプチドに結合する分子 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| ATE483472T1 (de) | 2002-05-30 | 2010-10-15 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| MX2007007935A (es) | 2004-12-28 | 2007-12-06 | Innate Pharma Sa | Anticuerpos monoclonales contra nkg2a. |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| MX2008015830A (es) | 2006-06-30 | 2009-01-09 | Novo Nordisk As | Anticuerpos anti-nkg2a y usos de los mismos. |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| JP5774312B2 (ja) | 2008-01-24 | 2015-09-09 | ノボ・ノルデイスク・エー／エス | ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体 |
| US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| EP2538973A2 (en) | 2010-02-26 | 2013-01-02 | Novo Nordisk A/S | Stable antibody containing compositions |
| WO2012172102A1 (en) | 2011-06-17 | 2012-12-20 | Novo Nordisk A/S | Selective elimination of erosive cells |
| EP3186282A1 (en) | 2014-08-28 | 2017-07-05 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations |
| SG10202007781TA (en) | 2014-09-16 | 2020-09-29 | Innate Pharma | Treatment Regimens Using Anti-NKG2A Antibodies |
| HUE051193T2 (hu) | 2014-09-16 | 2021-03-01 | Innate Pharma | Gátlási reakcióút semlegesítése limfocitákban |
| EP3659625A1 (en) | 2014-10-23 | 2020-06-03 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| WO2017106656A1 (en) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| LT3405495T (lt) | 2016-01-21 | 2021-08-10 | Innate Pharma | Inhibitorių kelių neutralizavimas limfocituose |
| EA202092147A1 (ru) | 2018-03-13 | 2021-03-04 | Иннейт Фарма | Лечение рака головы и шеи |
-
2019
- 2019-05-14 US US17/054,920 patent/US12209126B2/en active Active
- 2019-05-14 MA MA052627A patent/MA52627A/fr unknown
- 2019-05-14 AU AU2019270277A patent/AU2019270277B9/en active Active
- 2019-05-14 EA EA202092696A patent/EA202092696A1/ru unknown
- 2019-05-14 EP EP19728320.3A patent/EP3793607A1/en active Pending
- 2019-05-14 WO PCT/EP2019/062305 patent/WO2019219658A1/en not_active Ceased
- 2019-05-14 JP JP2020563542A patent/JP7531404B2/ja active Active
- 2019-05-14 CN CN201980031725.8A patent/CN112203691A/zh active Pending
- 2019-05-14 CA CA3099820A patent/CA3099820A1/en active Pending
- 2019-05-14 TW TW108116510A patent/TW202011989A/zh unknown
- 2019-05-14 SG SG11202011117VA patent/SG11202011117VA/en unknown
- 2019-05-14 KR KR1020207035232A patent/KR102885515B1/ko active Active
-
2020
- 2020-11-10 IL IL278618A patent/IL278618B2/en unknown
-
2024
- 2024-04-03 JP JP2024059910A patent/JP2024102055A/ja active Pending
-
2025
- 2025-01-14 AU AU2025200275A patent/AU2025200275A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024102055A5 (enExample) | ||
| KR102362920B1 (ko) | 항-her2 항체-약물 접합체 | |
| TWI868465B (zh) | 抗ｈｅｒ２抗體-藥物結合物之用途 | |
| IL278618B1 (en) | Cancer treatment | |
| JP2018503365A5 (enExample) | ||
| JP2018518454A5 (enExample) | ||
| JP2020514310A5 (enExample) | ||
| JP2018523493A5 (enExample) | ||
| US20250032633A1 (en) | Antibody-drug conjugate and application thereof | |
| JP2020526478A5 (enExample) | ||
| JP2010509931A5 (enExample) | ||
| CN106916227B (zh) | 一种tpbg抗体及其制备方法、其偶联物和应用 | |
| JPWO2020216697A5 (enExample) | ||
| US20200347140A1 (en) | Compositions and methods for treating cancer with anti-egfr antibodies | |
| JPWO2020014460A5 (enExample) | ||
| WO2021013061A1 (zh) | 一种人源化抗vegfr2抗体及其应用 | |
| JPWO2019160751A5 (enExample) | ||
| CN115485298A (zh) | 用于治疗癌症的egfr抑制剂和ror1抑制剂的组合 | |
| JPWO2019219658A5 (enExample) | ||
| JPWO2021123996A5 (enExample) | ||
| JPWO2023008462A5 (enExample) | ||
| JP2024532790A (ja) | 組換え抗ヒトｃｄ２５抗体及びその使用 | |
| JPWO2021190622A5 (enExample) | ||
| JPWO2021139776A5 (enExample) | ||
| JPWO2023008459A5 (enExample) |